Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.

Saved in:
Bibliographic Details
Title: Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
Authors: Bender JD; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH., Damodharan S; Department of Hematology, Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL.; Division of Hematology, Oncology and Bone Marrow Transplant, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI.; University of Wisconsin Carbone Cancer Center, Madison, WI., Capitini CM; Division of Hematology, Oncology and Bone Marrow Transplant, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI.; University of Wisconsin Carbone Cancer Center, Madison, WI., Moskop A; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Toner K; Division of Oncology, Children's National Hospital, Washington, DC.; Division of Blood and Marrow Transplantation, Children's National Hospital, Washington, DC.; Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC., Vatsayan A; Division of Blood and Marrow Transplantation, Children's National Hospital, Washington, DC.; Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC., Talano JA; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Baggott C; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Schiff D; Division of Hematology-Oncology, Rady Children's Hospital, San Diego, CA.; Department of Pediatrics, University of California San Diego, La Jolla, CA., Katsanis E; Department of Pediatrics, University of Arizona Cancer Center, University of Arizona, Tucson, AZ., Modi AJ; Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR., Quigg TC; Pediatric Blood and Marrow Transplant and Cellular Therapy Program, Helen DeVos Children's Hospital, Department of Pediatrics, Michigan State University College of Human Medicine, Grand Rapids, MI., Raikar SS; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA., Schultz LM; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Pommert L; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Source: Blood advances [Blood Adv] 2024 Aug 13; Vol. 8 (15), pp. 4164-4168.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024012928